In the treatment of colorectal cancer (CRC), osimertinib (OSI) can up-regulate the protein level of MCT1 and subsequently induce autophagy in CRC cells through LKB1-mediated activation of AMPK, thereby antagonizing the anti-tumor effect of OSI, but the mechanism may be independent of the monocarboxylate transport function of MCT1 (Jin et al., 2019). Here, SLC16A1 is linked to colorectal cancer.